Systemic Lupus Erythematosus, SLE

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that predominantly affects women of childbearing age. Pregnancy in SLE patients poses unique challenges due to risks of disease flares, maternal complications (e.g., preeclampsia, thrombosis), and adverse fetal outcomes (e.g., preterm birth, fetal growth restriction, neonatal lupus). Approximately 20-30% of SLE pregnancies experience flares, often triggered by hormonal shifts, with renal involvement being particularly detrimental. Preconception counseling is critical to optimize disease control (quiescent disease ≥6 months), adjust medications (e.g., avoid teratogens like methotrexate), and assess risks. Antiphospholipid antibodies (present in 30-40% of SLE patients) heighten thrombosis and pregnancy loss risks, necessitating anticoagulation (e.g., low-dose aspirin/heparin).  

Antiphospholipid Syndrome, APS

Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by persistent antiphospholipid antibodies (e.g., lupus anticoagulant, anticardiolipin antibodies) and clinical manifestations, including recurrent pregnancy loss, thrombosis, or placental insufficiency. In pregnancy, APS significantly increases risks of miscarriage (especially after 10 weeks), preeclampsia, fetal growth restriction (FGR), and preterm birth.  Management focuses on improving placental blood flow and preventing thrombosis. First-line therapy combines low-dose aspirin (initiated preconception) and prophylactic heparin (e.g., enoxaparin), reducing pregnancy loss risk by 50-75%.

Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a chronic autoimmune disease primarily causing joint inflammation and damage. During pregnancy, 50-75% of patients experience disease improvement due to immunomodulatory hormonal changes (e.g., elevated progesterone), though symptoms often flare postpartum. Uncontrolled RA may increase risks of preterm birth, low birth weight, and cesarean delivery. RA does not directly harm the fetus, but maternal disability or medication side effects (e.g., intrauterine growth restriction with long-term high-dose steroids) require vigilance. Delivery timing is typically at term unless complications arise. Postpartum, close monitoring and resumption of RA therapy (compatible with breastfeeding) are essential. Multidisciplinary care (rheumatology, obstetrics) ensures balanced maternal health and neonatal safety.

Sjögren's Syndrome

Sjögren's syndrome (SS) is a chronic autoimmune disorder characterized by lymphocytic infiltration of exocrine glands, leading to dry eyes/mouth, and systemic manifestations (e.g., fatigue, arthritis). In pregnancy, SS poses risks primarily linked to anti-SSA/Ro and anti-SSB/La antibodies, present in 60-70% of patients. These antibodies cross the placenta, increasing the risk of neonatal lupus (5-10% of cases) and congenital heart block (1-2%), which may require pacemaker implantation. Management includes hydroxychloroquine (reduces flares and neonatal complications), low-dose aspirin for APS overlap, and fetal echocardiography (weeks 18-24) to detect heart block. Serial ultrasounds monitor fetal growth, especially in anti-SSA/SSB-positive pregnancies. Symptomatic relief for dryness (artificial tears, saliva substitutes) is safe.